Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Ezetimibe, a cholesterol-absorption inhibitor, reduces levels of low-density lipoprotein (LDL) cholesterol when added to statin treatment. However, the effect of ezetimibe on the progression of atherosclerosis remains unknown. METHODS: We conducted a double-blind, randomized, 24-month trial comparing the effects of daily therapy with 80 mg of simvastatin either with placebo or with 10 mg of ezetimibe in 720 patients with familial hypercholesterolemia. Patients underwent B-mode ultrasonography to assess the intima-media thickness of the walls of the carotid and femoral arteries. The primary outcome measure was the change in the mean carotid-artery intima-media thickness, which was defined as the average of the means of the far-wall intima-media thickness of the right and left common carotid arteries, carotid bulbs, and internal carotid arteries. RESULTS: The primary outcome, the mean (+/-SE) change in the carotid-artery intima-media thickness, was 0.0058+/-0.0037 mm in the simvastatin-only group and 0.0111+/-0.0038 mm in the simvastatin-plus-ezetimibe (combined-therapy) group (P=0.29). Secondary outcomes (consisting of other variables regarding the intima-media thickness of the carotid and femoral arteries) did not differ significantly between the two groups. At the end of the study, the mean (+/-SD) LDL cholesterol level was 192.7+/-60.3 mg per deciliter (4.98+/-1.56 mmol per liter) in the simvastatin group and 141.3+/-52.6 mg per deciliter (3.65+/-1.36 mmol per liter) in the combined-therapy group (a between-group difference of 16.5%, P<0.01). The differences between the two groups in reductions in levels of triglycerides and C-reactive protein were 6.6% and 25.7%, respectively, with greater reductions in the combined-therapy group (P<0.01 for both comparisons). Side-effect and safety profiles were similar in the two groups. CONCLUSIONS: In patients with familial hypercholesterolemia, combined therapy with ezetimibe and simvastatin did not result in a significant difference in changes in intima-media thickness, as compared with simvastatin alone, despite decreases in levels of LDL cholesterol and C-reactive protein. (ClinicalTrials.gov number, NCT00552097 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although the earlier ENHANCE trial could not confirm that an addition of ezetimibe to statins significantly reduces intima-media thickness in patients with familial hypercholesterolemia, the SHARP and SEAS trials highlight ezetimibe’s role in the prevention of ischaemic cardiovascular events [62–65].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [65]
In the citing paper
“the SHARP and SEAS trials highlight ezetimibe’s role in the prevention of ischaemic cardiovascular events [62–65].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [65]
Citations
Cites
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
Self-citationBots, M. L., Hoes, A. W., Koudstaal, P. J., Hofman, A., & Grobbee, D. E. (1997) · Circulation · doi:10.1161/01.cir.96.5.1432 · Cited by 2,345
Self-citationNiemann-Pick C1 Like 1 Protein Is Critical for Intestinal Cholesterol Absorption
Altmann, S. W., Davis, H. R., Zhu, L.-J., Yao, X., Hoos, L. M., Tetzloff, G., Iyer, S. P. N., Maguire, M., Golovko, A., Zeng, M., et al. (2004) · Science · doi:10.1126/science.1093131 · Cited by 1,577
Pedersen, T. R. (2005) · JAMA · doi:10.1001/jama.294.19.2437 · Cited by 1,548
Self-citationBuchwald, H., Varco, R. L., Matts, J. P., Long, J. M., Fitch, L. L., Campbell, G. S., Pearce, M. B., Yellin, A. E., Edmiston, W. A., Smink, R. D., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199010043231404 · Cited by 1,001
Smilde, T., van Wissen, S., Awollersheim, H., Trip, M., Kastelein, J., & Stalenhoef, A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04053-8 · Cited by 918
Self-citationTaylor, A. J., Sullenberger, L. E., Lee, H. J., Lee, J. K., & Grace, K. A. (2004) · Circulation · doi:10.1161/01.cir.0000148955.19792.8d · Cited by 890
The safety of statins in clinical practice
Armitage, J. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60716-8 · Cited by 833
Cited by
Items 501–600 of 1,000
Rediscovering bile acid sequestrants
Bell, D. S. H., & O’Keefe, J. H. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01134.x · Cited by 19
Escárcega, R. O., García‐Carrasco, M., Jara, L. J., & Cervera, R. (2009) · Lupus · doi:10.1177/0961203308101435 · Cited by 18
Effect of Ezetimibe on Major Atherosclerotic Disease Events and All-Cause Mortality
Hayek, S., Canepa-Escaro, F., Sattar, A., Gamalski, S., Wells, K. E., Divine, G., Ahmedani, B. K., Lanfear, D. E., Pladevall, M., & Williams, L. K. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.11.002 · Cited by 17
Miller, M. J., DiNicolantonio, J. J., Can, M., Grice, R., Damoulakis, A., & Serebruany, V. L. (2013) · Cardiology · doi:10.1159/000347134 · Cited by 17
Cicero, A. F. G., Bove, M., & Borghi, C. (2017) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1416094 · Cited by 18
“The co-administration of ezetimibe with a statin confirmed remarkable efficacy results on the lipid profile in several clinical trials [8,16,17], and a relevant CVD preventive”
BackgroundA Control-Theoretic Model of Atherosclerosis
Formanowicz, D., Krawczyk, J. B., Perek, B., & Formanowicz, P. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030785 · Cited by 17
“Some relevant real-life IMT measurements are reported in [65].”
BackgroundResultInfluentialMuddy waters: more stormy SEAS for ezetimibe
Wierzbicki, A. S. (2008) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2008.01888.x · Cited by 17
Therapeutic Options to Further Lower C-Reactive Protein for Patients on Statin Treatment
Joshi, P. H., & Jacobson, T. A. (2010) · Current Atherosclerosis Reports · doi:10.1007/s11883-009-0075-x · Cited by 17
“ENHANCE [23] 720 patients with familial hypercholesterolemia Ezetimibe/simvastatin (80mg/d) vs simvastatin 80mg/d −25.7% (P=0.01) treatment difference in hsCRP in combination vs simvastatin Fibrate + statin therapy DIACOR [24] 300 type 2 diabetes patients with dyslipidemia Fenofibrate/simvastatin 20; mg/d vs fenofibra…”
BackgroundMethodInfluentialColesevelam hydrochloride: a specifically engineered bile acid sequestrant
Manghat, P., & Wierzbicki, A. S. (2008) · Future Lipidology · doi:10.2217/17460875.3.3.237 · Cited by 17
“The only surrogate outcome data available with ezetimibe have been disappointing in the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) study, with no benefit on cIMT being shown in patients with familial hypercholesterolemia receiving ezetimibe therapy on top of maximal…”
BackgroundHeterozygous familial hypercholesterolaemia in childhood: Cardiovascular risk prevention
van der Graaf, A., Kastelein, J. J. P., & Wiegman, A. (2009) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-009-1165-1 · Cited by 17
“Ezetimibe 10 mg monotherapy reduces LDL-C by 17–19% in adults (Knopp et al. 2003) and combination therapy with various statins in hypercholesterolaemic adults show an incremental decrease of LDL-C of approximately 15% (Ballantyne et al. 2003; Davidson et al. 2002; Kastelein et al. 2008).”
BackgroundSelf-citationWhat Combination Therapy with a Statin, If Any, Would You Recommend?
Dujovne, C. A., Williams, C. D., & Ito, M. K. (2010) · Current Atherosclerosis Reports · doi:10.1007/s11883-010-0150-3 · Cited by 17
“Enhances Atherosclerosis Regression (ENHANCE) trial was a randomized, double-blind, placebo-controlled trial comparing simvastatin 80 mg combined with ezetimibe 10 mg versus simvastatin 80 mg alone administered once daily in 720 patients with heterozygous familial hypercholesterolemia (HeFH) [ 16 ].”
MethodMasiá, M., Bernal, E., Padilla, S., García, N., Escribano, J. C., Martínez, E., & Gutiérrez, F. (2009) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp250 · Cited by 20
Lottenberg, A. M., Bombo, R. P. A., Ilha, A. O. G., Nunes, V. S., Nakandakare, E. R., & Quintão, E. C. R. (2012) · IUBMB Life · doi:10.1002/iub.1006 · Cited by 17
“Despite these therapeutic advances, ezetimibe has not been shown to be effective in human atherosclerosis (5).”
BackgroundLDL-Cholesterol-Lowering Therapy
Pirillo, A., Norata, G. D., & Catapano, A. L. (2020) · Handbook of experimental pharmacology · doi:10.1007/164_2020_361 · Cited by 18
Spence, J. D., & Rundek, T. (2011) · Springer eBooks · doi:10.1007/978-1-84882-688-5_25 · Cited by 17
Documento Abordaje de la dislipidemia. Sociedad Española de Arteriosclerosis (parte III)
Núñez-Cortés, J. M., Alegría, E., Álvarez-Sala, J. L., Gimilio, J. A., Lahoz, C., Morató, T. M., Prieto, J. M. M., Pedro‐Botet, J., & Pintó, X. (2011) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2011.09.004 · Cited by 26
Hamilton‐Craig, I. R., Kostner, K., Colquhoun, D. M., & Woodhouse, S. P. (2009) · Heart Lung and Circulation · doi:10.1016/j.hlc.2009.02.007 · Cited by 19
Angelopoulos, J., Krassakopoulos, N., Nathanson, R., Boukas, S., & Sampalis, J. S. (2009) · Cited by 17
Clinical Update on Nursing Home Medicine: 2008
Messinger‐Rapport, B. J., Thomas, D. R., Gammack, J. K., & Morley, J. E. (2008) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2008.07.006 · Cited by 17
Target cardiovascular risk rather than cholesterol concentration
Krumholz, H. M. (2013) · BMJ · doi:10.1136/bmj.f7110 · Cited by 17
The impact of clinical trials legislation on clinical pharmacology: problems and solutions
Brown, M. J. (2009) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03379.x · Cited by 17
Fuchs, F. D., Fuchs, Moreira, & Gus (2012) · Vascular Health and Risk Management · doi:10.2147/vhrm.s32585 · Cited by 17
“Ezetimibe reduced LDL-C by approximately 16% in addition to the effect of statins, but failed to reduce the carotid intima-media thickness in patients with familial hypercholesterolemia.(19) Compared to niacin, ezetimibe did not reduce carotid intima–media thickness and was associated with higher incidence of cardiova…”
Impact of the ENHANCE Trial on the use of ezetimibe in the United States and Canada
Lu, L., Krumholz, H. M., Tu, J. V., Ross, J. S., Ko, D. T., & Jackevicius, C. A. (2014) · American Heart Journal · doi:10.1016/j.ahj.2014.01.014 · Cited by 16
Ezetimibe: Rescued by Randomization (Clinical and Mendelian)
McPherson, R., & Hegele, R. A. (2014) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.114.305012 · Cited by 16
Expanding the therapeutic landscape: ezetimibe as non-statin therapy for dyslipidemia
Lee, J., & Lee, S. (2023) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2023.243 · Cited by 17
Surrogate endpoints in randomized cardiovascular clinical trials
DOMANSKI, M. J., Pocock, S., Bernaud, C., BORER, J. S., Geller, N. L., Revkin, J. H., & Zannad, F. M. (2010) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.2010.00865.x · Cited by 16
Sternberg, Z., Chichelli, T., Sternberg, D. S., Hojnacki, D. W., Drake, A. S., Liu, S., Hu, Q., & Munschauer, F. E. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.09.031 · Cited by 16
Guyton, J. R. (2010) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32833c1f16 · Cited by 17
Julve, J., Llaverías, G., Blanco‐Vaca, F., & Escolá‐Gil, J. C. (2011) · Current Vascular Pharmacology · doi:10.2174/157016111794519264 · Cited by 17
Ara, R., Pandor, A., Tumur, I., Paisley, S., Duenas, A., WILLIAMS, R., WILKINSON, A., Durrington, P. N., & Chilcott, J. B. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.08.002 · Cited by 17
Smith, M. B., Lee, E., Haney, E. M., & Carson, S. (2009) · Cited by 16
Lipid-lowering effects of ezetimibe and simvastatin in combination
Ijioma, N., & Robinson, J. G. (2011) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.10.179 · Cited by 17
Keizer, H. G. (2012) · Lipids in Health and Disease · doi:10.1186/1476-511x-11-149 · Cited by 20
Imaging as a surrogate marker of drug efficacy in cardiovascular disease
Tarkin, J. M., Dweck, M. R., & Rudd, J. H. F. (2018) · Heart · doi:10.1136/heartjnl-2017-311213 · Cited by 18
Diabetes Mellitus and Cardiovascular Disease
Frankel, D. S., Wilson, P. W. F., & Meigs, J. B. (2010) · Springer eBooks · doi:10.1007/978-1-4419-5839-6_11 · Cited by 16
Statintherapy in the primary and the secondary prevention of ischaemic cerebrovascular diseases
Feher, A., Pusch, G., Koltai, K., Tibold, A., Gasztonyi, B., Szapáry, L. B., & Fehér, G. (2010) · International Journal of Cardiology · doi:10.1016/j.ijcard.2010.08.012 · Cited by 17
Iron and Atherosclerosis: Nailing Down a Novel Target with Magnetic Resonance
Sharkey‐Toppen, T., Tewari, A. K., & Raman, S. V. (2014) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-014-9551-y · Cited by 17
“Despite known limitations in measurement accuracy and reliability [99, 100], clinical trials have relied on C-IMT as an outcome measure [101].”
Potential effect of ezetimibe against Mycobacterium tuberculosis infection in type II diabetes
Tsai, I., Kuo, C., Lin, A. B., Chien, M.-N., Ho, H., Wei, T., Wu, C., & Lu, Y. (2016) · Respirology · doi:10.1111/resp.12948 · Cited by 18
The Editor's Roundtable: The JUPITER Trial—Initial Results and Clinical Implications
Ridker, P. M., Friedewald, V. E., Davidson, M. H., Willerson, J. T., & Roberts, W. C. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.02.023 · Cited by 16
Reiman, E. M., & Langbaum, J. B. S. (2009) · Imaging the Aging Brain · doi:10.1093/acprof:oso/9780195328875.003.0020 · Cited by 16
Ledford, H. K. (2008) · Nature · doi:10.1038/452510a · Cited by 16
Coronary Artery Disease Prevention
Sherazi, S., & Block, R. (2009) · Springer eBooks · doi:10.1007/978-1-84882-185-9_2 · Cited by 15
The Need for Combination Drug Therapies in Patients with Complex Dyslipidemia
Barnett, J., Viljoen, A., & Wierzbicki, A. (2013) · Current Cardiology Reports · doi:10.1007/s11886-013-0391-1 · Cited by 13
Tunceli, K., Sajjan, S. G., Ramey, D. R., Neff, D., Tershakovec, A. M., Hu, X., Tomassini, J. E., & Foody, J. M. (2010) · Journal of clinical lipidology · doi:10.1016/j.jacl.2010.10.004 · Cited by 15
Chan, J. C. N., Chan, S. P., Deerochanawong, C., Go, R. T., Lee, K., Ronald, C. W., Pan, C., Sheu, W. H., & Barter, P. J. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2011.05.034 · Cited by 17
“failed to show beneficial effects on the surrogate end point of carotid intima-media thickness regression compared with placebo [74].”
BackgroundEzetimibe in Combination With a Statin Does Not Reduce All-Cause Mortality
Patel (2013) · Journal of Clinical Medicine Research · doi:10.4021/jocmr1371w · Cited by 15
“There was a dramatic fall in ezetimibe prescriptions after articles with negative and inconclusive findings were published, therefore new prescriptions after January 1st, 2008 were also excluded [5].”
BackgroundMethodInfluentialMeschia, J. F., Bushnell, C., Boden-Albala, B. M., Braun, L. T., Bravata, D. M., Chaturvedi, S., Creager, M. A., Eckel, R. H., Fornage, M., Goldstein, L. B., et al. (2014) · Cited by 15
The Impact of Information Technology on the Diffusion of New Pharmaceuticals
Arrow, K. J., Bilir, L. K., & Sorensen, A. (2020) · American Economic Journal Applied Economics · doi:10.1257/app.20170647 · Cited by 15
“It is important to note, however, that, our results indicate database adopters are primarily quicker to prescribe new generic drugs, which are not advertised.(41) Relatedly, it is possible in Table 5 that a physician’s decision to adopt the database is partially determined by the underlying, idiosyncratic rate of incr…”
Zhou, R., Stouffer, G. A., & Smith, S. C. (2021) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484211023632 · Cited by 15
Blom, D. J., Gaudet, D., Hegele, R. A., Patel, D. S., Cegla, J., Kolovou, G. D., & Masana, L. (2022) · Advances in Therapy · doi:10.1007/s12325-021-02031-y · Cited by 15
“In the ENHANCE trial [26], most participants were enrolled from lipid clinics and had been treated aggressively prior to enrolment.”
BackgroundSelf-citationArabi, S. M., Chambari, M., Malekahmadi, M., Bahrami, L. S., Hadi, V., Rizzo, M., & Sahebkar, A. (2022) · Inflammopharmacology · doi:10.1007/s10787-022-01053-4 · Cited by 15
“Finally, 57 studies were included in the qualitative synthesis, and 53 studies were included in the quantitative synthesis (meta-analysis) (Tan et al. 2021; Oh et al. 2019a, b; Oh et al. 2021; Oh et al. 2020; Sakuma et al. 2019; Kim et al. 2018a, b; Hibi et al. 2018; Wang et al. 2016; Wang et al. 2017; Ren et al. 2017…”
Risks and Benefits of Statin Use in Young People with Type 1 Diabetes
Bjornstad, P., & Wadwa, R. P. (2014) · Current Diabetes Reports · doi:10.1007/s11892-014-0499-8 · Cited by 17
Davidson, M. H., Rosenson, R. S., Maki, K. C., Nicholls, S. J., Ballantyne, C. M., Setze, C. M., Carlson, D. M., & Stolzenbach, J. C. (2012) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-012-6395-z · Cited by 15
“Thirteen studies that used simple mean change from baseline (7 studies) or regression models (6 studies) were analyzed to determine the common standard deviation (SD) for the annual progression rate (Table 1) [31, 34–46].”
MethodAl‐Rasadi, K., Al-Zakwani, I. S., Almahmeed, W. A., Arafah, M., Al-Hinai, A. T., Shehab, A. M., Tamimi, O. A., & Alawadhi, M. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.965774 · Cited by 15
Metabolomic strategies to identify tissue-specific effects of cardiovascular drugs
Jänis, M. T., Laaksonen, R., & Orešič, M. (2008) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.4.6.665 · Cited by 15
“However, recent results of the ENHANCE trial conducted among patients with familial hypercholesterolemia indicate that despite decreases in LDL cholesterol, combined therapy with ezetimibe and simvastatin did not result in a significant difference in intima-media thickness, compared with simvastatin monotherapy [103].”
ResultInherited metabolic disorders and cerebral infarction
Kalidas, K., & Behrouz, R. (2008) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.8.11.1731 · Cited by 18
The ezetimibe controversy: implications for clinical practice
Khanderia, U., Regal, R. E., Rubenfire, M., & Boyden, T. F. (2011) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944711410099 · Cited by 16
“The first challenge to the efficacy of ezetimibe came from the ENHANCE trial (Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression) [Kastelein et al. 2008] that included 720 patients with heterozygous familial hypercholesterolemia who received simvastatin plus either ezetimibe or place…”
BackgroundDifferences in synthesis and absorption of cholesterol of two effective lipid-lowering therapies
Kasmas, S. H., Izar, M. C. D. O., França, C. N., Ramos, S. C., Moreira, F. T., Helfenstein, T., Moreno, R. A., Borges, N. C. D. C., Neto, A. M. F., & Fonseca, F. A. H. (2012) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2012007500118 · Cited by 15
“On the other hand, the benefits of LDL cholesterol lowering using other strategies seem less clear (32-34).”
BackgroundMakkar, K. M., Sanoski, C. A., Goldberg, L. R., & Spinler, S. A. (2013) · Annals of Pharmacotherapy · doi:10.1177/1060028013504077 · Cited by 15
Azar, M., Valentin, E. D., Badaoui, G., Kassab, R., Sarkis, A., & Azar, R. R. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2011.01.038 · Cited by 15
Controlling the thickness of the atherosclerotic plaque by statin medication
Formanowicz, D., & Krawczyk, J. B. (2020) · PLoS ONE · doi:10.1371/journal.pone.0239953 · Cited by 15
Kostakou, P. M., Kolovou, G. D., Anagnostopoulou, K. K., Theodoridis, T., Galea, V., Mihas, C. C., Christopoulou-Cokkinou, V., & Cokkinos, D. V. (2010) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2009.10.003 · Cited by 16
More- Versus Less-Intensive Lipid-Lowering Therapy: Systematic Review and Meta-Analysis
Toyota, T., Morimoto, T., Yamashita, Y., Shiomi, H., Kato, T., Makiyama, T., Nakagawa, Y., Saito, N., Shizuta, S., Ono, K., et al. (2019) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.118.005460 · Cited by 16
Clinical benefits of ezetimibe use: is absence of proof, proof of absence?
Gouni‐Berthold, I., Mikhailidis, D. P., & Rizzo, M. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.720974 · Cited by 15
“The first of a series of some surprising findings regarding ezetimibe, a drug that decreases LDL-C by up to 20%, appeared in 2008, when the eagerly awaited Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial was published showing no benefit of the drug (when added to s…”
BackgroundHuman genetic insights into lipoproteins and risk of cardiometabolic disease
Stitziel, N. O. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000389 · Cited by 14
Planning primary prevention of coronary disease
Lands, B. (2009) · Current Atherosclerosis Reports · doi:10.1007/s11883-009-0042-6 · Cited by 15
“Recent evidence from the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial [ 18 ] caused the mass media to openly question whether the CVD-associated biomarker, elevated LDL cholesterol, is caused by factors that also cause CVD and whether cholesterol drugs actually…”
BackgroundEmerging options in the treatment of dyslipidemias: a bright future?
Florentin, M., Liberopoulos, E. N., Mikhailidis, D. P., & Elisaf, M. (2011) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2011.554395 · Cited by 14
“However, its role in CVD outcomes has been recently debated [9,63-65].”
BackgroundInfluentialIcosapent Ethyl for Treatment of Elevated Triglyceride Levels
Nelson, S. D., & Munger, M. A. (2013) · Annals of Pharmacotherapy · doi:10.1177/1060028013504079 · Cited by 14
Furman, A., Meier, J. L., Malmstrom, R., Lopez, J. R., & Schaefer, S. (2011) · PubMed · Cited by 15
Statin therapy across the lifespan: evidence in major age groups
Stone, N. J., Turin, A., Spitz, J. A., Valle, C. W., & Kazmi, S. (2015) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2016.1128825 · Cited by 14
Fei, Y., Guyatt, G. H., Alexander, P. E., Dib, R. E., Siemieniuk, R. A. C., Vandvik, P. O., Nunnally, M., Gomaa, H. A., Morgan, R. L., Agarwal, A., et al. (2017) · Journal of Evaluation in Clinical Practice · doi:10.1111/jep.12663 · Cited by 15
“Despite the effect on LDL‐cholesterol, randomized controlled trials (RCTs) have reported mixed results as to whether the addition of ezetemibe to statin therapy can offer additional protection against clinical vascular events.(6,7) Reflecting on this uncertainty, the 2013 treatment guidelines of the American Heart Ass…”
BackgroundOh, M., Kim, H., Shin, E. W., Sung, C., Kim, D.-H., Moon, D. H., & Lee, C. W. (2019) · BMC Cardiovascular Disorders · doi:10.1186/s12872-019-1184-2 · Cited by 15
Pharmacotherapy in familial hypercholesterolemia - Current state and emerging paradigms
Kallapur, A. S., & Sallam, T. (2021) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2021.12.011 · Cited by 14
Thomopoulos, C., Skalis, G., Michalopoulou, H., Tsioufis, C. P., & Makris, T. (2015) · Clinical Cardiology · doi:10.1002/clc.22441 · Cited by 14
Green, C. O., Wheatley, A. O., McGrowder, D. A., Dilworth, L., & Asemota, H. N. (2010) · Journal of Food Biochemistry · doi:10.1111/j.1745-4514.2010.00479.x · Cited by 14
The Future of Conflicts of Interest: A Call for Professional Standards
Lo, B. (2012) · The Journal of Law Medicine & Ethics · doi:10.1111/j.1748-720x.2012.00677.x · Cited by 14
Tsujita, K., Sugiyama, S., Sumida, H., Shimomura, H., Yamashita, T., Yamanaga, K., Komura, N., Sakamoto, K., Ono, T., Oka, H., et al. (2015) · Journal of Cardiology · doi:10.1016/j.jjcc.2014.12.011 · Cited by 14
Low-Density Lipoprotein Cholesterol Reduction and Prevention of Cardiovascular Disease
Stein, E. A. (2009) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)60537-5 · Cited by 16
Self-citationXu, H., Jiang, H., Yang, W., Song, F., Yan, S., Wang, C., Fu, W., Li, H., Lyu, C., Gan, Y., et al. (2019) · British Journal Of Nutrition · doi:10.1017/s0007114519001107 · Cited by 14
Arimura, T., Miura, S., Ike, A., Sugihara, M., Iwata, A., Nishikawa, H., Kawamura, A., & Saku, K. (2012) · Journal of Cardiology · doi:10.1016/j.jjcc.2012.03.002 · Cited by 14
Encouraging appropriate treatment for familial hypercholesterolemia
Hopkins, P. N. (2010) · Clinical Lipidology · doi:10.2217/clp.10.22 · Cited by 15
Pollak, A. W., & Kramer, C. M. (2012) · Clinical Lipidology · doi:10.2217/clp.12.6 · Cited by 18
Therapies Targeting Exogenous Cholesterol Uptake: New Insights and Controversies
Davidson, M. H. (2010) · Current Atherosclerosis Reports · doi:10.1007/s11883-010-0151-2 · Cited by 13
Assessment of Low-Density Lipoprotein Targets
Whayne, T. F. (2012) · Angiology · doi:10.1177/0003319712451115 · Cited by 14
Newsom, L. C. (2014) · Annals of Pharmacotherapy · doi:10.1177/1060028014564181 · Cited by 13
Evolving targets for lipid‐modifying therapy
Do, R. Q., Nicholls, S. J., & Schwartz, G. G. (2014) · EMBO Molecular Medicine · doi:10.15252/emmm.201404000 · Cited by 13
“In a study of patients with heterozygous familial hypercholesterolemia followed for 24 months, there was no difference in intima-media thickness with ezetimibe and simvastatin, compared with placebo and simvastatin (Kastelein et al , 2008).”
Grape juice attenuates left ventricular hypertrophy in dyslipidemic mice
Martins, Â. M., Sarto, D. A. Q. S., Caproni, K. D. P., Silva, J., da Silva, J. W., Souza, P. S., dos Santos, L., Ureña, M. J. E., Carvalho, M. D. G. D. S., Boas, B. M. V., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0238163 · Cited by 13
Robinson, J. G. (2008) · Vascular Health and Risk Management · doi:10.2147/vhrm.s3190 · Cited by 14
“In ENHANCE, ezetimibe 10 mg added to high dose simvastatin therapy had no signifi cant effect on carotid intimal medial thickness (CIMT) over a 2-year period in 720 subjects with familial hypercholesterolemia (FH).(47) ENHANCE differed in 2 important ways from the earlier Atorvastatin versus Simvastatin on Atheroscler…”
Maron, D. J., Hartigan, P. M., Neff, D., Weintraub, W. S., & Boden, W. E. (2013) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2013.02.005 · Cited by 13
Bourque, J. M., Schietinger, B. J., Kennedy, J. L. W., Pearce, E. A., Christopher, J. M., Taylor, A. M., McNamara, C. A., & Kramer, C. M. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.02.048 · Cited by 13
Teramoto, T., Sawada, T., Iwamoto, K., & Daida, H. (2012) · Current Therapeutic Research · doi:10.1016/j.curtheres.2012.02.002 · Cited by 13
de Miguel-García, F., Merino-Senovilla, A., Montero-Alonso, M. J., Ortiz, A. G., Cantalapiedra, R. S., & Maderuelo-Fernández, J. Á. (2010) · Revista Española de Salud Pública · doi:10.1590/s1135-57272010000200006 · Cited by 13
Kaneda, H., Terashima, M., & Yamaguchi, H. (2012) · Current Atherosclerosis Reports · doi:10.1007/s11883-012-0234-3 · Cited by 13
“Although recent studies using another frequently used imaging modality (carotid ultrasonography, n0720, n0208) failed to demonstrate significant differences of change of carotid intima-media thickness between groups [78, 79], a larger clinical study (n09270) demonstrated a significant reduction in major atheroscleroti…”
ResultQi, Y., Liu, J., Ma, C., Wang, W., Liu, X., Wang, M., Lv, Q., Sun, J., Liu, J., Li, Y., et al. (2013) · Journal of Lipid Research · doi:10.1194/jlr.p040360 · Cited by 14
Magnussen, C. G., Thomson, R. J., Juonala, M., Viikari, J. S. A., Dwyer, T., Raitakari, O. T., & Venn, A. (2011) · Journal of Ultrasound in Medicine · doi:10.7863/jum.2011.30.3.363 · Cited by 13
The Role of Ezetimibe in the Treatment of Cardiovascular Disease
Agarwala, A., Kajani, Z., Miedema, M. D., & Virani, S. S. (2016) · Current Atherosclerosis Reports · doi:10.1007/s11883-016-0560-y · Cited by 13
Warnings Without Guidance: Patient Responses to an FDA Warning About Ezetimibe
Shrank, W. H., Choudhry, N. K., Tong, A., Myers, J. A., Fischer, M. A., Swanton, K., Slezak, J., Brennan, T. A., Liberman, J. N., Moffit, S., et al. (2012) · Medical Care · doi:10.1097/mlr.0b013e31825517b6 · Cited by 13
Ershova, A. I., Boytsov, S. A., Drapkina, O. M., & Балахонова, Т. В. (2018) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2018-8-92-98 · Cited by 15
Frigerio, B., Werba, J. P., Amato, M., Ravani, A. L., Sansaro, D., Coggi, D., Vigo, L., Tremoli, E., & Baldassarre, D. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666191213120339 · Cited by 13
The Role of Non-statin Lipid-Lowering Medications in Youth with Hypercholesterolemia
Butt, W. Z., & Yee, J. K. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01013-x · Cited by 13
Metadata
- Authors
- Kastelein, J. J. P., Akdim, F., Stroes, E. S. G., Zwinderman, A. H., Bots, M. L., Stalenhoef, A. F. H., Visseren, F. L. J., Sijbrands, E. J. G., Trip, M. D., Stein, E. A., Gaudet, D., Duivenvoorden, R., Veltri, E. P., Marais, A. D., & de Groot, E.
- Affiliations
- Amsterdam UMC Location University of Amsterdam (NL)
- University Medical Center Utrecht (NL)
- Radboud University Nijmegen (NL)
- Erasmus MC (NL)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-04-03
- Volume
- 358
- Issue
- 14
- Pages
- 1431-1443
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2120289695
- Semantic Scholar
- 0da4a48a4d402878a4b01330a3e43a185140f586
- Cited by
- 1,241
- References
- 34
- Citations by year
- 2026: 8 · 2025: 13 · 2024: 16 · 2023: 20 · 2022: 14 · 2021: 24 · 2020: 27 · 2019: 35 · 2018: 30 · 2017: 38 · 2016: 50 · 2015: 77 · 2014: 91 · 2013: 85 · 2012: 111
- FWCI
- 210.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- Radboud Repository (Radboud University) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Disease Prevention
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- simvastatin, ezetimibe, familial hypercholesterolemia, LDL cholesterol lowering, atherosclerosis progression, carotid intima-media thickness, femoral artery, cholesterol absorption inhibition, triglycerides, C-reactive protein, statin combination therapy, lipid-lowering therapy, atherosclerotic plaque regression
- MeSH terms
- Ezetimibe, Adult, Anticholesteremic Agents, Azetidines, Carotid Arteries, Cholesterol, Double-Blind Method, Drug Therapy, Combination, Female, Femoral Artery, Humans, Hyperlipoproteinemia Type II, Cholesterol, LDL, Male, Middle Aged, Triglycerides, Ultrasonography, Treatment Outcome, Tunica Intima, Tunica Media, Simvastatin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.